NAS:GLPG (Belgium)
Business Description
Compare
Compare
Traded in other countries / regions
GLPG.Austria
•
GLPG.Belgium
•
G1LP34.Brazil
•
GXE.Germany
•
GLPG.Netherlands
•
0JXZ.UK
•
GLPG.USA
Description
Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 184.13 | |||||
| Equity-to-Asset | 0.53 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 1.97 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 1.67 | |||||
| Beneish M-Score | -2.27 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 11.4 | |||||
| 3-Year EBITDA Growth Rate | -33.7 | |||||
| 3-Year EPS without NRI Growth Rate | -45.5 | |||||
| 3-Year FCF Growth Rate | -42 | |||||
| 3-Year Book Growth Rate | 21.8 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | -0.68 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 8.79 | |||||
| 9-Day RSI | 17.87 | |||||
| 14-Day RSI | 23.95 | |||||
| 6-1 Month Momentum % | -19.43 | |||||
| 12-1 Month Momentum % | -6.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.23 | |||||
| Quick Ratio | 8.18 | |||||
| Cash Ratio | 8.04 | |||||
| Days Inventory | 1139.71 | |||||
| Days Sales Outstanding | 56.39 | |||||
| Days Payable | 7532.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.4 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 98.61 | |||||
| Operating Margin % | -32.77 | |||||
| Net Margin % | -15.96 | |||||
| ROE % | -3.05 | |||||
| ROA % | -1.54 | |||||
| ROIC % | -22.74 | |||||
| ROC (Joel Greenblatt) % | -29.49 | |||||
| ROCE % | -0.85 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 87.68 | |||||
| PS Ratio | 5.66 | |||||
| PB Ratio | 1.06 | |||||
| Price-to-Tangible-Book | 1.17 | |||||
| EV-to-EBIT | 39.39 | |||||
| EV-to-EBITDA | -126.93 | |||||
| EV-to-Revenue | -3.07 | |||||
| EV-to-FCF | 2.63 | |||||
| Price-to-Projected-FCF | 0.49 | |||||
| Price-to-Net-Current-Asset-Value | 1.33 | |||||
| Price-to-Net-Cash | 1.4 | |||||
| Earnings Yield (Greenblatt) % | 2.54 |
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GLPG
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 559.835 | ||
| EPS (TTM) ($) | -1.41 | ||
| Beta | 0 | ||
| Volatility % | 33.84 | ||
| 14-Day RSI | 23.95 | ||
| 14-Day ATR ($) | 1.398013 | ||
| 20-Day SMA ($) | 48.069 | ||
| 12-1 Month Momentum % | -6.29 | ||
| 52-Week Range ($) | 42.15 - 72.11 | ||
| Shares Outstanding (Mil) | 65.73 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Galapagos NV Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Galapagos NV Analysis
Share your researchHeadlines
See More
No news.